Comparison of Solifenacin with Mirabegron Versus Solifenacin with Vaginal Estrogen Cream for Treating Overactive Bladder in Women

What this Trial Is About

This research evaluates treatments for women with detrusor overactivity who did not respond to anti-muscarinic medications. It compares the effects of combining solifenacin with mirabegron against solifenacin combined with vaginal estrogen cream. The study aims to understand how these treatment combinations affect urinary symptoms and quality of life. Participants are divided into two groups one receives solifenacin 5mg daily with vaginal conjugated equine estrogen cream twice a week, while the other takes solifenacin 5mg plus mirabegron 25mg daily. The study monitors these treatments over time to assess their impact on bladder symptoms. Women in the study will have assessments before treatment and at 1 month, 3 months, 6 months, and 1 year after starting treatment. Researchers will evaluate urinary distress, incontinence impact, and overactive bladder symptoms using questionnaires, as well as track the number of daily urination episodes, urgency, incontinence, and nighttime urination. Safety and symptom changes will be closely monitored throughout the study period.

Efficacy of Combined Pharmacotherapy Versus Solifenacin With Vaginal Estrogen Cream for Women With Detrusor Overactivity